Ayahuasca Interactions

A

  • Amitriptyline - potential risk of serotonin syndrome; combination is strictly contraindicated due to risk of potentially life-threatening toxicities; consider tapering and discontinuing at least 2 weeks prior

B

  • Bupropion - potential increased risk of adverse effects; consider tapering and discontinuing at least 2 weeks prior

  • Buspirone - potential loss of psychedelic effect; consider tapering and discontinuing at least 2 weeks prior

C

  • Chlorpheniramine - potential high risk of serotonin syndrome; combination is strictly contraindicated due to risk of potentially life-threatening toxicities; consider tapering and discontinuing at least 2 weeks prior

  • Citalopram - potential risk of serotonin syndrome; combination is strictly contraindicated due to risk of potentially life-threatening toxicities; consider tapering and discontinuing at least 2 weeks prior

  • Clomipramine - potential high risk of serotonin syndrome; combination is strictly contraindicated due to risk of potentially life-threatening toxicities; consider tapering and discontinuing at least 2 weeks prior

D

  • Desipramine - potential risk of serotonin syndrome; combination is strictly contraindicated due to risk of potentially life-threatening toxicities; consider tapering and discontinuing at least 2 weeks prior

  • Desvenlafaxine - potential risk of serotonin syndrome; combination is strictly contraindicated due to risk of potentially life-threatening toxicities; consider tapering and discontinuing at least 2 weeks prior

  • Duloxetine - potential risk of serotonin syndrome; combination is strictly contraindicated due to risk of potentially life-threatening toxicities; consider tapering and discontinuing at least 2 weeks prior

E

  • Escitalopram - potential risk of serotonin syndrome; combination is strictly contraindicated due to risk of potentially life-threatening toxicities; consider tapering and discontinuing at least 2 weeks prior

F

  • Fluoxetine - adverse effects similar to serotonin toxicity (sweating, shivering, tremors, confusion, severe nausea, vomiting and disorientation); potential risk of serotonin syndrome; combination is strictly contraindicated due to risk of potentially life-threatening toxicities; consider tapering and discontinuing at least 6 weeks prior

  • Fluvoxamine - potential risk of serotonin syndrome; combination is strictly contraindicated due to risk of potentially life-threatening toxicities; consider tapering and discontinuing at least 2 weeks prior

I

  • Imipramine - potential high risk of serotonin syndrome; combination is strictly contraindicated due to risk of potentially life-threatening toxicities; consider tapering and discontinuing at least 2 weeks prior

  • Isocarboxazid - additive use of MAOIs may cause intensified experiences and/or cardiovascular collapse; consider tapering and discontinuing at least 2 weeks prior

L

  • Levomilnacipran - potential risk of serotonin syndrome; combination is strictly contraindicated due to risk of potentially life-threatening toxicities; consider tapering and discontinuing at least 2 weeks prior

M

  • Mirtazapine - potential loss of psychedelic effect; consider tapering and discontinuing at least 2 weeks prior

  • Moclobemide - additive use of MAOIs may cause intensified experiences and/or cardiovascular collapse; consider tapering and discontinuing at least 2 weeks prior

N

  • Nortriptyline - potential risk of serotonin syndrome; combination is strictly contraindicated due to risk of potentially life-threatening toxicities; consider tapering and discontinuing at least 2 weeks prior

P

  • Paroxetine - potential risk of serotonin syndrome; combination is strictly contraindicated due to risk of potentially life-threatening toxicities; consider tapering and discontinuing at least 2 weeks prior

  • Phenelzine - additive use of MAOIs may cause intensified experiences and/or cardiovascular collapse; consider tapering and discontinuing at least 2 weeks prior

S

  • Selegiline - additive use of MAOIs may cause intensified experiences and/or cardiovascular collapse; consider tapering and discontinuing at least 2 weeks prior

  • Sertraline - potential risk of serotonin syndrome; combination is strictly contraindicated due to risk of potentially life-threatening toxicities; consider tapering and discontinuing at least 2 weeks prior

T

  • Tranylcypromine - additive use of MAOIs may cause intensified experiences and/or cardiovascular collapse; consider tapering and discontinuing at least 2 weeks prior

  • Trazodone - potential loss of psychedelic effect; consider tapering and discontinuing at least 5 days prior

V

  • Venlafaxine - potential risk of serotonin syndrome; combination is strictly contraindicated due to risk of potentially life-threatening toxicities; consider tapering and discontinuing at least 2 weeks prior

  • Vilazodone - potential risk of serotonin syndrome; combination is strictly contraindicated due to risk of potentially life-threatening toxicities; consider tapering and discontinuing at least 2 weeks prior

  • Vortioxetine - potential risk of serotonin syndrome; combination is strictly contraindicated due to risk of potentially life-threatening toxicities; consider tapering and discontinuing at least 2 weeks prior

LSD

DMT